Variations in anti-dementia drug prescribing

Progress in Neurology and Psychiatry

Volumn 13, Issue 4, 2009, Pages 30-33

  Perecherla, Sri ^a   Paton, Carol ^b   Shingleton Smith, Amber ^d   Barnes, Thomas R E ^c  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b OXLEAS NHS FOUNDATION TRUST   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d Prescribing Observatory for Mental Health   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; GALANTAMINE; MEMANTINE; NOOTROPIC AGENT; RIVASTIGMINE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL PRACTICE; DEMENTIA; DRUG COST; EVIDENCE BASED MEDICINE; GENERAL PRACTITIONER; HEALTH CARE ORGANIZATION; MEDICAL AUDIT; MENTAL HEALTH CENTER; PRESCRIPTION; PRIMARY HEALTH CARE; PRIORITY JOURNAL;

EID: 70350257982     PISSN: 13677543     EISSN: None     Source Type: Journal    
DOI: 10.1002/pnp.131     Document Type: Article

References (13)

1. Dementia UK 2007. The full report. Alzheimer's society, UK. www.alzheimers.org.uk/downloads/Dementia_UK_Full_Report.pdf
2. National Institute for Health and Clinical Excellence. 2006. Dementia:A NICE-SCIE Guideline on supporting people with dementia and their carers in health and social care. National Clinical Practice Guideline Number 42. NICE. (www.nice.org.uk/nicemedia/pdf/CG42Dementiafinal.pdf)
3. The Information Centre for Health and Social Care. 2004. Attribution Data Set of GP Registered Populations. (www.ic.nhs.uk/ statistics-and-data- collections/population-and-geography/population/ population-figures-at-sha-and-pco-level-for-england and-wales)
4. NHS Information centre, 2006. Prescription Cost Analysis. www.ic.nhs.uk/ statistics-and-data-collections/primary-care/ prescriptions-cost-analysis-2006
5. Taylor D, Mace S, Fry C. The use of anti-cholinesterases for Alzheimer's disease in Britain. Pharm J 2001;266:263.
6. National Institute for Clinical Excellence, 2001. The use of donepezil, galantamine and rivastigmine for the treatment of mild to moderately severe Alzheimer's disease. Health Technology Assessment. 19. National Institute for Health and Clinical Excellence. www.nice.org.uk
7. Hillmer M, Krahn M, Hillmer M, et al. Prescribing patterns for Alzheimer Disease; survey of Canadian family physicians. Can Fam Physician 2006;52:208-9.
8. Sheldon TA, Cullun N, Dawson D, et al. What's the evidence that NICE guidance has been implemented? Results from a national evaluation using time series analysis, audit of patients' notes and interviews. BMJ 2004;329:999-1007.
9. Matthews FE, McKeith I, Bond J, et al. Reaching the population with dementia drugs: what are the challenges? Int J Geriatr Psychiatry 2007;22:627-31.
10. Johnell K, Weitoft GR, Fastbom J. Education and use of dementia drugs: a register-based study of over 600,000 older people. Dement Geriatr Cogn Disorder 2008;25:54-9.
11. Connolly CM, Bullock R. 2003. Treatment of patients with Alzheimer's disease: a national survey following release of the NICE guideline. Psychiatr Bull 27:11-3.
12. The Information Centre for Health and Social Care. 2008. Prescription cost analysis. England 2007. www.ic.nhs.uk/webfiles/publications/ PCA%20publication/PCA%20200720complete.pdf
13. Overshott R, Burns A. Cholinesterase inhibitors: in search of cholinergic deficits. Adv Psychiatr Treat 2005;11:321-4.